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Abstract
Context—Changes in reimbursements for clinical laboratory testing may help us assess the effect 
of various variables, such as testing recommendations, market forces, changes in testing 
technology, and changes in clinical or laboratory practices, and provide information that can 
influence health care and public health policy decisions. To date, however, there has been no 
report, to our knowledge, of longitudinal trends in national laboratory test use.
Objective—To evaluate Medicare Part B–reimbursed volumes of selected laboratory tests per 10 
000 enrollees from 2000 through 2010.
Design—Laboratory test reimbursement volumes per 10 000 enrollees in Medicare Part B were 
obtained from the Centers for Medicare & Medicaid Services (Baltimore, Maryland). The ratio of 
the most recent (2010) reimbursed test volume per 10 000 Medicare enrollees, divided by the 
oldest data (usually 2000) during this decade, called the volume ratio, was used to measure trends 
in test reimbursement. Laboratory tests with a reimbursement claim frequency of at least 10 per 10 
000 Medicare enrollees in 2010 were selected, provided there was more than a 50% change in test 
reimbursement volume during the 2000–2010 decade. We combined the reimbursed test volumes 
for the few tests that were listed under more than one code in the Current Procedural Terminology 
(American Medical Association, Chicago, Illinois). A 2-sided Poisson regression, adjusted for 
potential overdispersion, was used to determine P values for the trend; trends were considered 
significant at P < .05.
Results—Tests with the greatest decrease in reimbursement volumes were electrolytes, digoxin, 
carbamazepine, phenytoin, and lithium, with volume ratios ranging from 0.27 to 0.64 (P < .001). 
Tests with the greatest increase in reimbursement volumes were meprobamate, opiates, 
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methadone, phencyclidine, amphetamines, cocaine, and vitamin D, with volume ratios ranging 
from 83 to 1510 (P < .001).
Conclusions—Although reimbursement volumes increased for most of the selected tests, other 
tests exhibited statistically significant downward trends in annual reimbursement volumes. The 
observed changes in reimbursement volumes may be explained by disease prevalence and 
severity, patterns of drug use, clinical or laboratory practices, and testing recommendations and 
guidelines, among others. These data may be useful to policy makers, health systems researchers, 
laboratory directors, and industry scientists to understand, address, and anticipate trends in 
laboratory testing in the Medicare population.
Recognizing changes in reimbursement volume for clinical laboratory tests may help us 
assess the effect of test recommendations, inform new laboratory practice guidelines and 
recommendations or modify existing ones, and provide information for health care and 
public health policy decisions. In 1996, the US Centers for Disease Control and Prevention 
(CDC) evaluated laboratory test use in a random, stratified sample of US clinical 
laboratories to estimate clinical laboratory test volumes of the most commonly ordered 
analytes.1 That inventory of laboratory services provided a baseline for tracking changes in 
the access to laboratory tests and the effect of changes in the health care system for 
laboratory services, which may lead public regulatory and private accreditation systems 
toward any needed changes. However, the full value of that study was not realized because it 
was not repeated after 1996, and hence, the collected data are no longer relevant to current 
laboratory testing practices. There have been reports of longitudinal testing trends in specific 
areas of laboratory medicine, such as testing for influenza virus.2 However, there has been 
no report, to our knowledge, of longitudinal trends in the more common tests in various 
areas of laboratory medicine.
We present the reimbursement volumes per 10 000 enrollees in Medicare Part B for the most 
common laboratory tests and test panels from 2000 through 2010. These data, consequently, 
are derived primarily from testing of outpatients who are 65 years or older. We focused on 
analytes that had high reimbursement volumes with volumes that changed more than 50% 
during this decade. Many factors affect reimbursement trends, including evolving 
knowledge, national availability of testing systems and their ease of use as mediated by 
changes in laboratory technology, costs of testing, changing prevalence or incidence rates of 
diseases, changing disease severity, changing rates for screening and diagnostic workup of 
specific diseases, code use and revisions of the Current Procedural Terminology (CPT; 
American Medical Association, Chicago, Illinois), and changes in therapies that use existing 
or new tests, in addition to revised or new clinical and laboratory practice guidelines and 
recommendations. We examined the published literature for evidence of changes in 
laboratory practice guidelines and recommendations or other variables that might explain the 
observed changes in reimbursement volumes. During the study period, many publications 
provided guidance on the use of specific analytes, which may have affected their use. Many 
of the selected analytes, some included in one or more test panels, showed significant trends 
in their reimbursement volumes, and those specifically discussed in this report include 
fibrinogen3; high-sensitivity C-reactive protein (hs-CRP)4–6; brain natriuretic peptide 
(BNP)7–9; cardiac troponins7–13; thyroid-stimulating hormone (TSH)14–17; testosterone18,19; 
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human papillomavirus (HPV) DNA20–22; carbohydrate antigen (CA) 19-923–27; vitamin 
D28–30; hepatitis B virus (HBV) surface antigen31,32; hepatitis C virus (HCV) antibody33–35; 
Borrelia burgdorferi36; Clostridium difficile37,38; influenza virus2; and drugs of abuse, such 
as cocaine39; tacrolimus40,41; lithium42–45; antiepileptic drugs46; digoxin47; psychotropic 
drugs48; carbamazepine49; and phenytoin.50,51
MATERIALS AND METHODS
Reimbursement volumes for laboratory tests per 10 000 enrollees in Medicare Part B 
(defined as the normalized reimbursement volume and called simply reimbursement volume 
throughout this article) were obtained from the US Centers for Medicare & Medicaid 
Services. The ratio of the most recent (2010) reimbursement volume divided by the earliest 
volumes (usually 2000), called the volume ratio (VR), during this decade, was used as a 
measure of trends in test reimbursement volume. Laboratory tests were selected based on 
reimbursement claim frequency (at least 10 in 2010 per 10 000 Medicare enrollees). Another 
inclusion criterion was that there be a greater than 50% incremental change (increase or 
decrease) in test reimbursement volume during this decade. A few tests were listed under 
more than one CPT code; therefore, in those cases, reimbursement could be requested with 
more than one CPT code, and they were combined in our study. The CPT codes for 
reimbursement claims were dynamic during the decade, with some new codes added and 
others eliminated or changed. A 2-sided Poisson regression adjusted for potential 
overdispersion was used to determine the P value for trends; trends were considered 
significant at P < .05.
RESULTS
Enrollees in Medicare Part B, obtained from the US Centers for Medicare & Medicaid 
Services, increased steadily every year, from 37.4 million in 2000 to 44.0 million in 2010. 
The percentage of annual increase in the number of enrollees in Medicare Part B also 
increased from 0.9% in 2000–2001 (resulting from an increase from 37.4 million to 37.7 
million enrollees) to 2.3% in 2009–2010 (due to the population of Medicare Part B enrollees 
increasing from 43.0 million to 44.0 million enrollees). All the data have been adjusted for 
more Medicare Part B enrollees (approximately 18% from 2000 through 2010) by 
determining reimbursement per 10 000 enrollees. However, reimbursed laboratory tests per 
10 000 enrollees also increased by approximately 35% during the decade (from 64 200 in 
2000 to 86 700 in 2010).
Laboratory Test Panels
Reimbursement volumes per 10 000 enrollees in Medicare Part B for the most commonly 
reimbursed laboratory test panels, which also showed at least a 50% change in 
reimbursement volume during the past decade, are shown in Figure 1. Although there is a 
general downward trend in the reimbursement volume for liver function and electrolyte test 
panels, there is a general upward trend in the reimbursement volume for basic metabolic, 
lipid, comprehensive metabolic, and renal function tests when comparing the numbers of 
tests at the beginning and end of the decade. The caption to Figure 1 contains the list of 
laboratory tests each panel comprised. The trend in the reimbursement volumes of these test 
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panels may be considered in view of the test composition of each panel. For example, the 
comprehensive metabolic panel includes all 8 tests in the basic metabolic panel and all 4 
tests in the electrolyte panel, while also containing 6 of the 7 tests in hepatic function and 9 
of the 10 tests in renal function panels; and the 4 tests in the electrolyte panel are also 
included in comprehensive metabolic, basic metabolic, and renal function panels. Except for 
the basic metabolic panel, all test panels showed significant reimbursement volume trends 
with time (P ≤ .004).
Common Cancer, Cardiovascular, Coagulation, Diabetes, Hematology, and Renal Tests
In the general categories of cancer, cardiovascular, coagulation, diabetes, hematology, and 
renal tests, the most commonly reimbursed tests that were associated with at least a 50% 
change in reimbursement volume in 2000 through 2010 were tests for total prostate-specific 
antigen (PSA), total cholesterol, triglycerides, prothrombin time (reported either in seconds 
or as an international normalized ratio), glucose, glycohemoglobin, complete blood cell 
count, creatinine, and albumin levels. Reimbursement volumes per 10 000 enrollees for 
these tests in 2000 through 2010 are shown in Figure 2. All tests except PSA had 
significantly increasing trends in reimbursement volume (P ≤ .004). The trend for total PSA 
reimbursement volume during the past decade approached significance (P = .05).
Tests Used for Triage and Risk Assessment of Cardiovascular Diseases
Total cholesterol and triglycerides were the most commonly reimbursed tests for assessing 
risk of cardiovascular diseases, demonstrating at least a 50% change in reimbursement 
volume during the past decade. Commonly ordered tests, such as HDL-cholesterol and 
LDL-cholesterol, showed less than a 50% incremental change during the past decade, and 
hence, they were not included, even though lipid panel, including both of these tests, met the 
inclusion criteria. Other commonly reimbursed tests with at least 50% change in 
reimbursement volume used for triage and evaluation of risk for cardiovascular diseases 
were creatine kinase, C-reactive protein, BNP, hs-CRP, homocysteine, apolipoproteins, 
cardiac troponin, creatine kinase isoenzyme MB (CK-MB), and myoglobin tests. 
Reimbursement volumes per 10 000 enrollees for these tests from 2000 through 2010 are 
shown in Figure 3. Except for homocysteine, all of these tests had increasing reimbursement 
volumes and statistically significant trends (P ≤ .04). The increased reimbursement volumes 
were most pronounced for myoglobin, BNP, cardiac troponin, hs-CRP, and apolipoproteins 
(VR, 4–10).
Cancer Monitoring or Screening Tests
Following total PSA tests (Figure 2), the most commonly reimbursed tests for cancer 
monitoring or screening showing at least a 50% change in reimbursement volume during the 
past decade were those for cervicovaginal cytology, carcinoembryonic antigen, CA 15-3, 
free PSA, HPV DNA, CA 125, β2-microglubulin, α-fetoprotein, and CA 19-9. 
Reimbursement volumes per 10 000 enrollees for these tests from 2000 through 2010 are 
shown in Figure 4. All of these tests, except cervical cytology, showed increases in 
reimbursement volumes over time, and all trends were significant (P < .001). Most notable 
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was an approximately 60-fold increase in reimbursement volumes for HPV DNA testing 
from 2000 through 2010.
Hematology and Coagulation Tests
Excluding complete blood cell count and prothrombin time tests (Figure 2), the most 
reimbursed hematology and coagulation tests that also showed at least a 50% change in 
reimbursement volume during the past decade were tests for reticulocyte count, hemoglobin, 
partial thromboplastin time, fibrinogen, and fibrin degradation products. Reimbursement 
volumes per 10 000 enrollees for these tests from 2000 through 2010 are shown in Figure 5. 
There were increasing reimbursement volumes for all of these tests (up to 16-fold for fibrin 
degradation products), and all showed significant trends (P ≤ .03) with the exception of 
partial thromboplastin time.
Hormone Tests
The most commonly reimbursed hormone test showing at least a 50% change in 
reimbursement volume from 2000 through 2010 was TSH, showing increasing 
reimbursement volumes during this period, appearing to replace thyroxin alone or in 
combination with triiodothyronine. Reimbursement volumes per 10 000 enrollees for these 
tests from 2000 through 2010 are shown in Figure 6. There were increasing reimbursement 
volumes for other thyroid-related tests with a 7-fold change noted for free triiodothyronine. 
The most reimbursed hormone tests unrelated to the thyroid gland were tests for parathyroid 
hormone and testosterone, each showing an approximately 4-fold increase in reimbursement 
volumes from 2000 through 2010. All trends were significant (P < .001).
Hepatobiliary Tests
The most commonly reimbursed hepatobiliary tests showing at least a 50% change in 
reimbursement volumes from 2000 to 2010 were alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, total bilirubin, direct bilirubin, and lactate 
dehydrogenase. Reimbursement volumes per 10 000 enrollees for these tests from 2000 
through 2010 are shown in Figure 7. In contrast to decreasing reimbursement volumes for 
the liver function panel, there were increasing reimbursement volumes for the liver enzyme 
tests and for total bilirubin. However, tests for direct bilirubin and lactate dehydrogenase 
both showed decreasing reimbursement trends. All trends were significant (P ≤ .007).
Immunology and Nutrition Tests
Aside from albumin, the most commonly reimbursed nutrition and immunology tests 
showing at least a 50% change in reimbursement volumes from 2000 through 2010 were 
those tests for vitamin D, vitamin B12, allergen-specific immunoglobulin (Ig) E, folic acid, 
IgM, nuclear antigen antibody (antibodies against various nuclear antigens), antinuclear 
antibody, rheumatoid factor, prealbumin, and complement. Reimbursement volumes per 10 
000 enrollees for these tests from 2000 through 2010 are shown in Figure 8. There was 
increasing reimbursement for all of these tests, particularly for vitamin D, which showed 
greater than an 80-fold increase in test reimbursement volumes from 2000 through 2010. All 
trends were significant (P ≤ .007).
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The most commonly reimbursed infectious disease tests showing at least a 50% change in 
reimbursement volume from 2000 through 2010 in decreasing order of reimbursement 
volumes were those tests for HBV surface antigen, HBV surface antibody, HCV antibody, 
group A streptococcus antigen, Borrelia burgdorferi antibody, Helicobacter pylori (both 
antibody and antigen tests), Clostridium difficile antigen, HBV core antibody, and influenza 
virus antigen and antibody. Reimbursement volumes per 10 000 enrollees for these tests 
from 2000 through 2010 are shown in Figure 9. Excluding H pylori, there was increasing 
reimbursement for all tests, particularly for influenza virus, which showed more than a 30-
fold increase in test reimbursement volume from 2000 through 2010 with significant trends 
(P ≤ .002).
Tests for Monitoring of Therapeutic Drugs Not Generally Abused
Many therapeutic drugs have minimal potential for abuse. Among these, the most commonly 
reimbursed tests for therapeutic drug monitoring showing at least a 50% change in 
reimbursement volumes from 2000 through 2010 were those for digoxin, phenytoin, 
valproic acid, tacrolimus, meprobamate, carbamazepine, lithium, and vancomycin. 
Reimbursement volumes per 10 000 enrollees for these tests from 2000 through 2010 are 
shown in Figure 10. Decreasing reimbursement volumes were noted for digoxin, 
carbamazepine, phenytoin, lithium, and valproic acid. Increasing reimbursement volumes 
were observed for vancomycin and tacrolimus. All tests showed significant trends (P < .
001).
Tests for Monitoring of Drugs Used Therapeutically or Misused
The most commonly reimbursed tests showing at least a 50% change in reimbursement 
volume from 2000 to 2010 that were used either for monitoring of therapeutic drugs with 
potential for overuse or abuse or for determining use of illicit drugs, including those for 
opiates, methadone, benzodiazepine, amphetamine, phencyclidine, barbiturates, cocaine, 
ethanol, and meprobamate. Reimbursement volumes per 10 000 enrollees for these tests 
from 2000 through 2010 are shown in Figure 11. For these drugs, the same CPT code could 
be used for reimbursement, regardless of whether testing was performed to assure that drugs 
were within therapeutic range or to determine whether they were being misused. There were 
increasing reimbursement volumes for all of these tests, and all trends were significant (P < .
001).
Reimbursement Volume Trends
Of the 76 laboratory tests and the 6 test panels that met the inclusion criteria, 11 laboratory 
tests (14%) and 2 test panels (33%) exhibited decreased reimbursements volumes during the 
past decade (VR, 0.27–0.94), whereas 65 laboratory tests (86%) and 4 test panels (67%) 
showed increased reimbursement volumes (VR, 1.06–1510). The 5 laboratory tests and test 
panel (5 of 13; 38%) with the greatest decrease in reimbursement volumes from 2000 to 
2010 were electrolyte panel (VR, 0.27), digoxin (VR, 0.33), carbamazepine (VR, 0.48), 
phenytoin (VR, 0.53), and lithium (VR, 0.64). Of the 65 laboratory tests with increased 
reimbursement volumes, the top 14 (22%) were meprobamate (VR, 1510), opiates (VR, 
Shahangian et al. Page 6













532), methadone (VR, 461), phencyclidine (VR, 388), amphetamines (VR, 370), cocaine 
(VR, 132), vitamin D (VR, 83), barbiturates (VR, 60), HPV DNA (VR, 58), 
benzodiazepines (VR, 45), influenza virus (VR, 34), fibrin degradation products (VR, 16), 
ethanol (VR, 11), and myoglobin (VR, 10).
COMMENT
Many variables may have contributed to the laboratory reimbursement trends we have 
observed, including evolving knowledge of testing recommendations and guidelines; 
national availability, the cost of testing systems, and their ease of use; changing prevalence, 
incidence, or severity of diseases; changing rates of screening and diagnostic workup of 
specific diseases; changing reimbursement rates, which may result from CPT code revisions 
and rules for using the codes; changes in treatments modalities; and revision or introduction 
of practice guidelines and recommendations.
Tests Used for Triage and Risk Assessment of Cardiovascular Diseases
Comments relevant to selected tests with observed changes in reimbursement volumes used 
for triage and risk assessment in cardiovascular diseases (Figures 3 and 5) are discussed 
below.
Fibrinogen—Use of the fibrinogen test in coagulation panels tripled during the 6 years 
from 2000 to 2006 (Figure 5).3 Increasingly, the fibrinogen test is used with other cardiac 
risk markers to determine overall risk for cardiovascular disease. As an acute-phase reactant, 
fibrinogen, as well as CRP, provide added information that may lead to more-aggressive 
treatment to prevent cardiovascular diseases.3 The reimbursement volume for this test 
increased 3.8-fold from 2000 through 2010.
High-Sensitivity CRP—Myeloperoxidase and hs-CRP predict the risk of coronary heart 
disease in otherwise healthy individuals, allowing clinicians to initiate early preventive 
treatment.52 The predictive value of hs-CRP has been shown to be independent of traditional 
cardiovascular risk factors.53–55 The National Academy of Clinical Biochemistry convened 
a multidisciplinary, expert panel to develop laboratory medicine practice guidelines for a 
selected subset of emerging risk factors in the primary prevention of heart disease and stroke 
that included (apo)lipoproteins, hs-CRP, fibrinogen, homocysteine, and BNP. In 2009, that 
group concluded that only hs-CRP met all of the stated criteria required for acceptance as a 
biomarker for risk assessment in primary prevention.6 However, the US Preventive Services 
Task Force announced that same year that there was insufficient evidence to assess the 
balance of benefits and harms of hs-CRP screening to prevent cardiac events in 
asymptomatic individuals with no history of congestive heart disease.5 Data regarding the 
association of hs-CRP with cardiovascular disease are extensive and consistent; however, 
absent information on clinical relevance or cost-effectiveness, the role of hs-CRP in clinical 
practice remains unclear.4,56,57 This risk marker’s reimbursement began in 2002, peaked in 
2009, and declined in 2010 (Figure 3; P = .04).
Brain Natriuretic Peptide—Published literature supporting the use of BNP began to 
appear in 2003,58–60 and that was the first year this test was reimbursed under Medicare Part 
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B. There was a rapid increase in the reimbursement volume from 2003 until 2005, which 
continued, but more slowly, until 2008, when reimbursement volume began to plateau 
(Figure 3). When BNP was first introduced, associated data indicated clinical utility 
comparable to other methods for evaluating patients with heart failure.58–60 However, 
subsequent reports noted limited evidence supporting the use of the BNP test for diagnosis 
of cardiac dysfunction or heart failure in the elderly of 75 years and older.7 Current findings 
justify neither use nor confident rejection of BNP levels to inform the prognosis or diagnosis 
of heart failure,61 with recommendations for clinicians to cautiously interpret concentrations 
of BNP to predict the outcome of persons with coronary artery disease.62 Several markers 
identified in patients with heart failure have direct clinical relevance in aiding diagnosis, risk 
stratification, monitoring therapy, and treatment to improve clinical outcomes, including 
both BNP and hs-CRP.63 Preoperative BNP levels have considerable diagnostic value when 
used in addition to signs and symptoms, especially in patients younger than 75 years who 
are suspected of having heart failure in primary care.7,64 Elevated BNP levels have been 
helpful in diagnosing heart failure and in screening for left ventricular systolic 
dysfunction.65 For diagnosis in primary care, low BNP values may be used to rule out heart 
failure, but because of poor specificity, high values cannot be used to “rule in” the 
condition.66 Levels of BNP may help assess heart failure in a patient with dyspnea as well as 
providing information for making both triage and management decisions.58,60 Brain 
natriuretic peptide is a consistent, independent predictor of mortality in patient populations 
with risk of coronary artery disease, diagnosed coronary artery disease, and diagnosed heart 
failure.67 However, there is insufficient evidence to determine the value of BNP in screening 
for preclinical ventricular remodeling or dysfunction in the general population.59 There is 
insufficient evidence to demonstrate that BNP levels change in response to therapies that 
manage patients with stable chronic heart failure.67
Cardiac Troponin—In 2007, a joint task force of the European Society of Cardiology; 
American College of Cardiology Foundation; American Heart Association, Inc; and the 
World Heart Federation proposed a new definition for acute myocardial infarction based on 
detection of cardiac troponin and associated clinical evidence of myocardial ischemia.10 
Small increases in cardiac troponin concentration within reference limits are associated with 
increased odds of acute coronary syndrome.11 Meta-analysis provided evidence for an 
association between postoperative cardiac troponin release with midterm and short-term, all-
cause mortality after adult cardiac surgery.12 The National Academy of Clinical 
Biochemistry reported on the use of cardiac troponin and BNP for diagnosing etiologies 
other than acute coronary syndromes and heart failure,9 as well as on clinical characteristics 
and the use of biochemical markers in acute coronary syndromes.13 In patients with acute 
myocardial infarction, as well as in patients suffering from stable and unstable angina, 
measurement of cardiac troponin alone or combined with other biochemical markers is of 
practical value for the diagnosis, prognosis, and selection of the most effective therapeutic 
treatment, as well as for risk assessment. Figure 3 shows that there was an approximately 4-
fold increase in the reimbursement volume for cardiac troponin from 2000 through 2010, 
reflecting the increasing advocacy for this test as the marker of myocardial ischemia.
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Tests Used to Evaluate Endocrinologic Diseases and Conditions
Comments relevant to changes in reimbursement volumes for 2 tests used to evaluate 
endocrinologic diseases and conditions (Figure 6) are discussed below.
Thyroid-Stimulating Hormone—Laboratory tests are the most commonly used aids in 
the diagnosis and monitoring individuals with thyroid disease.17 Testing for TSH is a first-
line diagnostic procedure for assessment of thyroid function and, in some cases, may be the 
only diagnostic measure indicated.68 With increasing assay sensitivity and specificity, 
several programs in the United States and worldwide have switched to the use of TSH 
testing as a primary screening strategy for thyroid diseases,14 even though it is unknown 
whether that treatment is likely to improve the quality of life in otherwise healthy patients 
who have abnormal TSH and whose thyroxin levels are within reference range.15,69 There is 
evidence that mild thyroid dysfunction has adverse consequences and should not merely be 
regarded as a prognostic indicator; however, evidence is insufficient to support population-
based screening by using either TSH or the thyroxin test.70 Nevertheless, it may be 
appropriate to screen pregnant women, women older than 60 years, and others at higher risk, 
such as patients receiving psychotropic drugs (lithium, phenothiazines, and tricyclic 
antidepressants),71 for thyroid dysfunction because subclinical hyperthyroidism is associated 
with adverse effects on the skeleton and the heart, and it is best assessed by measuring 
serum TSH.16 However, there is no consensus on whether there is a causal relationship 
between mild thyroid failure and dyslipidemia.72 From 2000 to 2004, there was an 
approximately 1.5-fold increase in the reimbursement volume for TSH in the Medicare 
population, which has since been leveling off (VR, 1.72; see Figure 6), reflecting increasing 
use of the TSH test in the evaluation of, and screening for, thyroid diseases as promoted in 
some publications in the past decade and cited earlier.
Testosterone—Total testosterone should be measured in all men with erectile dysfunction 
in accordance with contemporary guidelines and particularly in those who have a chronic 
illness associated with low testosterone.18 Testosterone, the predominant androgen in men, 
when deficient, leads to a multiplicity of symptoms and signs that are corrected with 
physiologic substitution. When testosterone replacement is initiated, close monitoring for 
efficacy and safety is advised.19 From 2000 through 2010, there was an approximately 4-
fold increase in the reimbursement volume for testosterone testing, reflecting the increasing 
use of testosterone replacement therapy and monitoring promoted in media and in published 
literature (see Figure 6).18,19
Tests Used for Cancer Monitoring or Screening
We discuss below the changes observed in the reimbursement volume for 2 tests used to 
screen for or monitor malignant diseases (Figure 4).
Human Papillomavirus DNA—Testing for HPV DNA in cervical specimens increased 
in the past decade as a useful option for triaging women with equivocal diagnoses from 
Papanicolaou tests for follow-up colposcopy.73 Testing for HPV DNA improves diagnostic 
accuracy by limiting unnecessary colposcopy in patients with borderline or mildly abnormal 
cytologic test results.74 A strategy of combined cytology and HPV screening every 3 years 
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for women with dually negative results is more effective than cytology alone when 
colposcopies quantify the disease burden.20 However, a sensitivity analysis suggested that a 
strategy of HPV testing followed by cytology (for women with HPV+ test results) warranted 
further study.20 Current evidence has shown superiority of HPV testing over cervical 
cytology as a more-sensitive screening method and for follow-up of women treated for 
cervical intraepithelial neoplasia.75 Detection of HPV DNA has become an established tool 
for diagnosis and monitoring of HPV-related disease,76 given that persistent infection with 
HPV has been recognized as a significant risk factor for most precancerous lesions and 
cancers of the cervix.77 Although testing for HPV DNA in cervical specimens is more 
sensitive than the Papanicolaou test in detecting high-grade cervical lesions, HPV testing is 
less specific than cervical cytology,78 and it should be reserved for the more labor-efficient 
task of triaging patients with HPV+ test results because most HPV+ tests contain relevant 
abnormalities that can be evaluated by cervical cytology with sufficient accuracy.79 The 58-
fold increase in the reimbursement of HPV DNA testing from 2000 through 2010 (Figure 4) 
seems to reflect the increasing advocacy for the use of HPV DNA testing for cervical cancer 
screening.
Carbohydrate Antigen 19-9—In the 2006 recommendations by the American Society 
for Clinical Oncology on the use of tumor markers in gastrointestinal cancer, measuring CA 
19-9 was advocated every 1 to 3 months for patients with locally advanced or metastatic 
pancreatic cancer receiving active therapy, noting that elevations in serial CA 19-9 levels 
suggested progressive disease.26 The CA 19-9 levels provide critical information regarding 
survival that can help guide treatment of individuals diagnosed with pancreatic 
adenocarcinoma,80 and in patients with resected adenocarcinoma of the pancreas, high 
preoperative CA 19-9 levels are associated with adverse pathologic features and poorer 
survival,23 whereas low preoperative CA 19-9 levels are positively related to survival after 
resection of the pancreas.81 In advanced pancreatic cancer, pretreatment CA 19-9 levels 
have a prognostic effect regarding overall survival, and CA 19-9 decline under 
chemotherapy can provide prognostic information for median survival.82 Although several 
promising candidates have been identified as markers of pancreatic cancer, none has yet 
been convincingly proven to be better than CA 19-9,83 and it remains the most useful 
serologic marker for the diagnosis and follow-up of pancreatic cancer.84 The 1.4% increase 
in the incidence of pancreatic cancer between 2000 and 200985 may explain a small part of 
the increasing reimbursement rate for CA 19-9. Reported incidence rates refer to the entire 
US population, however, whereas the population in this study was composed of individuals 
who are 65 years and older. Testing for CA 19-9 was first reimbursed in 2001, when it was 
deemed to be of value in monitoring patients with pancreatic cancer. This test was 
increasingly used in the Medicare population between 2001 and 2010 (VR, 4.5; see Figure 
4), reaching a plateau in 2008. The increasing popularity of this test in monitoring for 
pancreatic cancer and the increase in the incidence rate of this cancer85 may explain part of 
the increasing trend in this test’s reimbursement.
Nutritional Assessment Test
We discuss below the dramatic increase in the reimbursement volume for vitamin D (Figure 
4).
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Vitamin D—Testing for Vitamin D deficiency and supplementation has been increasingly 
advocated in the past decade. Vitamin D deficiency is increasingly implicated in many 
diseases, and its deficiency is common in all age groups because of lack of sun exposure and 
the few foods containing sufficient amounts of this vitamin.29,86 Older adults pose a 
particular challenge, not only because vitamin D deficiency results in abnormal metabolism 
of calcium and causes diseases such as osteoporosis, osteomalacia, and osteopenia, which 
become more prevalent with aging but also because there are often complications with other 
comorbidities.29 Accumulating evidence from experimental, clinical, and epidemiologic 
studies suggests that vitamin D may be associated with several indices of vascular function, 
including the development and progression of atherosclerotic cardiovascular disease, and 
several recent epidemiologic studies has implicated low vitamin D status in the pathogenesis 
of cardiovascular disease.30 The Endocrine Society Task Force recommended 
supplementation at tolerable upper-limit levels depending on age and clinical circumstances, 
and further recommended measurement of serum 25-hydroxyvitamin D levels as the initial 
diagnostic test in patients at risk for deficiency.28 However, evidence-based consensus 
guidelines are not available for use of laboratory tests for vitamin D status for medical 
management and screening of individuals, and observational studies of correlations between 
25-hydroxyvitamin D and clinical outcomes are subject to confounding results and do not 
prove causation.86 Nevertheless, from 2000 through 2010, there was an 83-fold increase in 
the reimbursement volume for vitamin D, part of which may be explained by the numerous 
publications advocating increasing use and measurement of this vitamin, as well as by the 
increasing coverage in the media triggered by those publications (Figure 8).28–30,86
Infectious Disease Tests
Comments relevant to selected tests with observed changes in reimbursement volumes used 
in the evaluation of infectious diseases (Figure 9) are discussed below.
Hepatitis B Virus—Early identification of chronic HBV infection enables treatment 
interventions to prevent or delay onset of liver disease by identifying and vaccinating 
susceptible individuals (household contacts and sex partners of HBV-infected persons, 
pregnant women, persons born in countries with hepatitis B surface antigen prevalence .8%, 
and persons who are the source of blood or body fluid exposures that might warrant 
postexposure prophylaxis) and, hence, interrupting ongoing transmission.87 In 2008, the 
CDC published new recommendations for routine testing of several additional populations: 
those with hepatitis B surface antigen prevalence of at least 2%, those born in geographic 
regions with hepatitis B surface antigen prevalence of at least 2%, men who have sex with 
men, and injection-drug users.31 Serologic and nucleic acid testing are critical to disease 
prevention and treatment objectives,32 and information from such testing helps to determine 
patients’ infectivity and immune status, appropriate monitoring strategies, efficacy of 
treatment, and provision of data that may contribute to a better understanding of the natural 
history and epidemiology of this infection. These screening recommendations31,87 and 
disease prevention strategies32 may have contributed to the increase in the reimbursement 
volume for hepatitis B surface antigen by approximately 1.4-fold between 2000 and 2010 
(Figure 9). However, this increase in reimbursement volume occurred in 2000 through 2005 
in response to earlier screening87 and disease prevention32 recommendations, and the effect 
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of the CDC’s latest recommendation in expanding the screening population31 seems not to 
have been realized yet.
Hepatitis C Virus—The HCV infection is a complex public health problem, characterized 
by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, 
low rates of testing and treatment, and the prospect of increasing incidence associated with 
the epidemic of injection drug use.88 Testing for HCV antibody has been recommended for 
at-risk populations, including confirmatory quantification by polymerase chain reaction, if 
positive.89 Although antiviral treatment may successfully eradicate HCV, the available data 
in 2004 on long-term outcomes in populations identified by screening were lacking.35 
Although targeted screening, particularly among intravenous drug users, may identify 
substantially higher incidence than found in the general population, data have been 
inadequate to accurately weigh the overall benefits and harms of screening in otherwise 
healthy, asymptomatic adults. Recommendations to screen for HCV infection in populations 
overlapping those of Medicare Part B enrollees33,35,88,89 may explain, at least in part, the 
increase in reimbursement volume for HCV antibody test of approximately 1.8-fold from 
2000 through 2010 (Figure 9).
Lyme Disease—Serologic testing for Lyme disease should be used judiciously because it 
may produce misdiagnosis when performed on patients with a low prior probability of 
disease or nonspecific symptoms, such as fatigue or arthralgia, without objective signs of 
infection.36 The purpose of laboratory testing for Borrelia burgdorferi infection is to confirm 
a clinician’s judgment of possible Lyme disease. Detection of antibodies to B. burgdorferi is 
a practical and common approach for evaluating a patient with suspected Lyme disease; 
however, serologic testing is recommended only when there is at least 1 in 5 chance (20%), 
in the clinician’s estimation, that the patient has active Lyme disease.36 Comparing 2 recent 
5-year intervals, the incidence of reported Lyme disease in the United States increased 34% 
from approximately 81 000 (1997–2001) to approximately 108 000 (2002–2006).90 
Increasing incidence of Lyme disease during the past decade,90 coupled with greater utility 
of serologic testing when this disease becomes more prevalent,36 may explain the increasing 
reimbursement volume for Lyme disease testing by approximately 2-fold from 2000 through 
2010 (Figure 9).
Clostridium difficile: Laboratory diagnosis of Clostridium difficile infections has increased 
because of the numbers of people and severity of this infection.37 During the past 20 years, 
the prevalence of health care–associated C. difficile disease has increased. Repeat testing, 
although of limited utility, is common in medical practice.38 In 5% of cases during outbreak 
settings, testing for C. difficile is repeated at least once. Repeat C. difficile testing for 
hospitalized patients has low clinical utility but may be considered in outbreak settings or 
when the pretest probability of disease is high.38 Increasing numbers of people with, and the 
severity of, this infection,37 coupled with the common practice of repeat testing,38 may have 
contributed to the increasing reimbursement volume for C. difficile antigen testing by 
approximately 2.5-fold from 2000 through 2010 (Figure 9).
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Influenza Virus—Diagnostic tests for influenza virus have become increasingly important 
because some emerging strains pose pandemic potential. Influenza testing is critical for 
directing global influenza prevention and control activities2 and is increasing, as evidenced 
by reimbursement volume increasing by approximately 5-fold from the 2000– 2001 to the 
2009–2010 season.91 There has been an even more dramatic increase in reimbursement 
volume in the Medicare population by approximately 34-fold from 2000 through 2010, and 
that increase appears to relate to recent pandemics (see the spike in 2009 in Figure 9).
Drug Testing
Comments relevant to observed changes in the reimbursement volumes for the tests used in 
detecting and monitoring of selected drugs are discussed below (see Figures 10 and 11).
Tacrolimus—Tacrolimus is superior to cyclosporine in improving survival from 
transplantation grafts and in preventing acute rejection after kidney transplantation; 
however, its use increases posttransplant diabetes with demonstrated neurologic and 
gastrointestinal side effects.92 Although reimbursement volume for tacrolimus increased by 
approximately 3.4-fold from 2000 through 2010, the reimbursement volume for 
cyclosporine decreased by 0.46-fold (data not shown). In 2000, the ratio of reimbursement 
volume for cyclosporine over tacrolimus was approximately 1.5. That ratio decreased 
consistently during the past decade until it reached 0.19 in 2010. Treating 100 recipients 
with tacrolimus instead of cyclosporine would cause 12 patients to avoid acute rejection and 
2 to avoid losing their grafts, but cause an extra 5 patients to become insulin-dependent 
diabetics.40,92 After renal transplantation, immunosuppression with tacrolimus significantly 
reduced acute rejection compared with cyclosporine.41 Follow-up studies of high 
methodologic quality are needed to determine whether tacrolimus indeed improves long-
term renal graft survival. With the increasing popularity of tacrolimus as an 
immunosuppressant for patients having transplants, there has been an increase in the 
reimbursement volume for tacrolimus test by approximately 3.4-fold from 2000 through 
2010 (Figure 10).
Lithium—Lithium is a first-line drug for treating patients with major depression who do not 
respond adequately to standard antidepressants.42 Lithium reduces suicidal acts and 
completed suicide; however, there are significant side-effect burdens, narrow therapeutic 
indices, and prolonged treatment requirements.43 As an antidepressive, lithium is not 
recommended as monotherapy because newer antidepressants and anticonvulsants are better 
tolerated and more effective.44 Lithium use for bipolar disorder has decreased in the United 
States,45 and that may be a contributing factor to the decrease in the reimbursement volume 
for lithium monitoring in the Medicare population by approximately 0.6-fold from 2000 
through 2010 (Figure 10).
Digoxin—The use and dosage of digoxin have declined, with an accompanied decline in 
hospitalizations for digoxin toxicity in the United States, calling into question whether 
digoxin is increasingly underused, given that guidelines continue to recommend this drug for 
both heart failure and atrial fibrillation.47 The number of prescriptions written for at least 
250 µg of digoxin has decreased, and the public health burden of digoxin toxicity has 
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declined dramatically from 1991 to 2004, with its use in atrial fibrillation decreasing over 
time.47 In the United States, digoxin use declined from 76% (191 of 252) in patients with 
atrial fibrillation in 1980–1981 to 37% (105 of 285) in such patients in 1999–2000, 
reflecting reports that digoxin is less effective than beta-blockers or calcium channel 
blockers in controlling tachycardia, despite no concomitant increase in the use of other 
agents used to control cardiac arrhythmia.93 In agreement with earlier observations that 
seem to reflect an increasing concern about digoxin toxicity and its use, and given 
availability of other agents for control of heart rate, there has been a decrease in the 
reimbursement volume for digoxin monitoring in the Medicare population by approximately 
0.3-fold from 2000 through 2010 (Figure 10).
Carbamazepine—Antiepileptic drug use has changed gradually from 1993 to 2006.49 
More individuals are prescribed lamotrigine than carbamazepine, and that mirrors a 
corresponding decrease in carbamazepine monitoring. There has been a decrease in the 
reimbursement volume for total carbamazepine monitoring in the Medicare population by 
approximately 0.5-fold from 2000 through 2010 (Figure 10), which reflects decreasing 
prescription rate for this drug.
Phenytoin—For those older than 65 years, there was a small reduction in the use of 
phenytoin (71% (1300 of 1840) to 66% (1160 of 1760) from 1998 to 2004 as an 
antiepileptic drug. Despite a growing list of clinical recommendations and guidelines for 
newer antiepileptic drugs, phenytoin was the most commonly used drug in this category, and 
there was little change in its use for elderly patients during those 6 years.50 However, in 
another study,51 phenytoin accounted for 40% (111 420 of 282 080) of treated person-years 
in 1993 declining to 18% (51 620 of 282 080) by 2008. There has been a decrease in the 
reimbursement volume for total phenytoin monitoring in the Medicare population by 
approximately 0.5-fold from 2000 to 2010 (Figure 10), reflecting increasing use of other 
newer antiepileptic drugs.
Other Drugs—Department of Health and Human Services’ guidelines for the workplace 
require testing for drugs of abuse, including amphetamines, cannabinoids, cocaine, opiates, 
and phencyclidine.94,95 Testing may determine whether a therapeutic level has been 
maintained, to detect potential abuse in a patient being treated with the drug, or to detect 
abuse in an individual not using a drug for legitimate treatment. However, the same CPT 
code in each case is used regardless of the indications for testing. These drugs, shown in 
Figure 11, include analgesics, tranquilizers, and depressants (opiates, methadone, 
benzodiazepines, barbiturates, phencyclidine, ethanol, and meprobamate) as well as 
stimulants (amphetamine and cocaine). From 2000 through 2010, reimbursement volume for 
these tests increased from approximately 11-fold for ethanol to approximately 1500-fold for 
meprobamate. The change in CPT coding that occurred just before 2000 allowed for 
reimbursement of testing for single drugs in either therapeutic drug monitoring or chemistry 
sections of the clinical laboratory, which may have contributed to a large increase in the 
volume of drug testing, further aggravated by the increase in drug abusers as well as patients 
taking various pain medications.94
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Demands for drug testing to document adherence to, or avoidance of, prescribed drugs with 
both therapeutic and abuse potential has increased as reflected by the US Food and Drug 
Administration’s risk evaluation and mitigation strategies proposed for opioids, as well as 
clinical practice guidelines that have been published by entities such as the American 
Society of Interventional Pain Physicians96 and the State of Washington,97 and provided 
information98 and initiatives99 by the CDC. Clinicians are more interested in testing for pain 
relievers, reflected by more pain management laboratories profiting from rapid, automated, 
lessexpensive, and noninvasive test methods.100 Urine drug testing has greatly increased 
during recent years101 because urine is a specimen of choice for method of collection, 
method of analysis, and results interpretation. Adherence monitoring, including controlled 
substance agreements and various periodic measures of compliance, has been associated 
with a 49% reduction in opioid abuse.102 Drug screening tests are typically competitive 
immunoassays with antibodies directed against drug groups or classes. Therefore, individual 
drugs, such as morphine, codeine, or heroin, cannot be identified or quantitated, requiring a 
more-specific test, such as gas chromatography combined with mass spectrometry, to 
confirm the presence and quantity of each specific analyte. Urine drug testing of patients 
taking pain medications, however, can be an effective means to augment pharmacotherapy 
and to assist with complex medical and legal aspects of the current health care 
environment.103 The demand for clinical testing of drugs in urine for pain management has 
increased dramatically as clinicians, regulatory agencies, and payers seek objective 
measures to regulate compliance and support clinical diagnoses.
The growth of specialty laboratories and the marketing efforts targeting physician office 
practices, may partly explain the increased reimbursement trend data seen in Figure 11 
because the pain management testing industry has evolved into a multimillion dollar 
business with laboratories specializing in this type of testing and because more clinicians are 
looking for guidance, feeling they are constantly faced with the difficult decision to 
prescribe medications, particularly to their older patients who experience pain more often for 
controlling their pain and improving their daily activities, whereas, at the same time, 
realizing the high abuse and addiction rates associated with the use of these medications.101 
There has been an increasing trend in emergency department visits that has involved 
nonmedical use of various pharmaceuticals between 2004 and 2009.104 In 2009, 48% 
(approximately 516 000 of 1 079 700) of such visits were due to the use of pain relievers; 
and emergency department visits due to pain reliever use increased by 114% from 241 600 
in 2004 to 516 000 in 2009. This included increases of 141% in visits (from approximately 
172 700 to 416 500) due to use of opiates, 137% (from approximately 144 600 to 342 600) 
due to narcotic pain relievers (including 71% increase in emergency department visits (from 
approximately 36 800 to 63 000) due to use of methadone), and 118% (from approximately 
143 500 to 312 900) due to benzodiazepines (see Table 19 of the 2011 report by the 
Substance Abuse and Mental Health Services Administration).104 Emergency department 
visits due to nonmedical use of stimulants increased by 122% (from approximately 9800 to 
21 740) for the same period, including 276% increase (from 2303 to 8656) in visits due to 
use of amphetamines.
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The relative reimbursement volumes of tests in this study generally agree with the relative 
volumes estimated for the most commonly ordered tests in the 1996 CDC survey of US 
laboratories conducted 17 years ago.1 Our study presents the paid reimbursement volume 
per 10 000 enrollees in Medicare Part B for tests or panels of tests, as opposed to requests 
for reimbursement, but only for enrollees in Medicare Part B. These results cannot be 
equated to actual laboratory test volumes performed. In addition, Part B reimbursements 
cover only outpatient, not inpatient, testing. Nevertheless, to our knowledge, this is the only 
published report of longitudinal trends in test reimbursement volume for a broad group of 
laboratory tests that relate mostly to the US population age 65 years or older. Trends shown 
here can be expected to reflect the overall laboratory use rates in that population. The 
presented data cannot be generalized to the population younger than 65 years, and even for 
the population cohort age 65 years and older, the numbers for each year include only 
reimbursement under Medicare Part B. Despite these limitations, the data presented in this 
report may be useful to policy makers, health systems researchers, laboratory managers, and 
industry scientists in addressing and anticipating trends in the use of laboratory tests in the 
evaluation of the health of the Medicare-eligible US population.
Reimbursement volumes for all laboratory tests or panels can be obtained by going to a US 
Centers for Medicare & Medicaid Services Web site,105 which also provides volume data 
for all nonlaboratory tests or procedures.
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Reimbursement volumes for common laboratory test panels. Comprehensive metabolic 
panel: glucose, calcium, albumin, total protein, sodium, potassium, CO2, chloride, urea 
nitrogen, creatinine, ALP, ALT, AST, bilirubin. Lipid panel: total cholesterol, high-density 
lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides. Basic metabolic 
panel: glucose, calcium, sodium, potassium, CO2, chloride, urea nitrogen, bilirubin. Liver 
function panel: ALT, AST, ALP, bilirubin, direct bilirubin, albumin, total protein. Renal 
function panel: creatinine, urea nitrogen, albumin, calcium, CO2, chloride, glucose, 
phosphorus, potassium, sodium. Electrolyte panel: sodium, potassium, CO2, chloride. 
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; VR, volume ratio (see “Materials and Methods”).
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Reimbursement volumes for the most common cancer, cardiovascular, coagulation, diabetes, 
hematology and renal tests. Abbreviations: PSA, prostate-specific antigen; VR, volume ratio 
(see “Materials and Methods”) .
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Reimbursement volumes for tests used for triage and risk assessment of cardiovascular 
diseases. Abbreviations: CK-MB, creatine kinase MB isoenzyme; hs-CRP, high-sensitivity 
C-reactive protein; VR, volume ratio (see “Materials and Methods”).
Shahangian et al. Page 24














Reimbursement volumes for tests used for cancer monitoring or screening. Abbreviations: 
CA, carbohydrate antigen; CEA, carcinoembryonic antigen; HPV, human papillomavirus; 
PSA, prostate specific antigen; VR, volume ratio (see “Materials and Methods”).
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Reimbursement volumes for hematology and coagulation tests. Abbreviations: FDPs, fibrin 
degradation products; PTT, partial thromboplastin time; VR, volume ratio (see “Materials 
and Methods”).
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Reimbursement volumes for hormone tests. Abbreviations: PTH, parathyroid hormone; T4, 
thyroxin, T3, triiodothyronine; TSH, thyroid-stimulating hormone; VR, volume ratio (see 
“Materials and Methods”).
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Reimbursement volumes for hepatobiliary tests. Abbreviation: VR, volume ratio (see 
“Materials and Methods”).
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Reimbursement volumes for immunology and nutrition tests. Abbreviations: IgM, 
immunoglobulin M; VR, volume ratio (see “Materials and Methods”).
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Reimbursement volumes for infectious disease tests. Abbreviations: B burgdorferi, Borrelia 
burgdorferi; HBV, hepatitis B virus; HCV, hepatitis C virus; H pylori, Helicobacter pylori; 
strep, streptococcus bacteria; VR, volume ratio (see “Materials and Methods”).
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Reimbursement volumes for tests used in therapeutic drug monitoring. Abbreviations: VR, 
volume ratio (see “Materials and Methods”).
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Reimbursement volumes for tests to monitor drugs used therapeutically, overused, or 
abused. Some of these are urine-based tests. Abbreviation: VR, volume ratio (see “Materials 
and Methods”).
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